Selphagy Therapeutics | Boston; New York
Autophagy is the process by which young cells recycle “junk.” Selphagy is developing the first drugs that restore autophagy in so-called “lysosomal storage diseases” during old age. Co-founded by Drs. Ana Maria Cuervo and Evris Gavathiotis, Selphagy has identified new chemical entities with a molecular target to activate autophagy.
Aging Component: Loss of Proteostasis
Developing ways to boost the body's ability to remove damaged and misfolded proteins that are believed to cause aging. The technology has applications in treating vision loss, Alzheimer's and rare genetic diseases.
Senolytic Therapeutics | Boston; Barcelona | Website
Senolytic Therapeutics is developing new compounds and technologies that specifically target “zombie” senescent cells for destruction. Using proprietary strategies to target these cells, co-founders Drs. Manuel Serrano and Marc Ramis Castelltort are advancing therapies to treat biological aging and associated diseases.
Aging Component: Cellular Senescence
Developing unique approaches to kill off "zombie" or senescent cells in the body, which are believed to underlie the aging process.
Aging Component: Stem Cell Exhaustion
Developing ways to remove senescent cells and allow stem cells to expand and renew tissues.
Jumpstart Fertility, Inc. | Boston; Sydney
Drs. Lindsay Wu and Hayden Homer are developing medicines intended to improve egg cell quality and restore fertility in women of advancing age or who have experienced premature infertility. These molecules may go well beyond improving fertility.
Aging Component: Chromosomal Instability
Focused on how to prevent DNA damage and reverse aging in the ovary, potentially restoring a woman's ability to produce healthy, viable eggs.
Aging Component: Epigenetic Alterations
Developing medicines that restore a more youthful "epigenome" to improve egg cell quality in the female reproductive system to reverse infertility.
Continuum Biosciences | Blacksburg, VA; Sydney
Scientists from Continuum have discovered self-limiting uncouplers that are highly specific to mitochondria. Co-founders Drs. Kyle Hoehn and Webster Santos are working with their team to fine-tune the effectiveness of their compounds to address obesity, diabetes, liver disease, and other conditions that decrease lifespan.
Aging Component: Mitochondrial Dysfunction
Developing new molecules that restore the metabolic engine of the aged cell, thereby reducing damage from free-radicals.
Aging Component: Metabolism
Taking a fresh look at metabolic diseases. By forcing the cell to use more nutrients to produce the same amount of energy, they can induce fat loss and potentially treat metabolic diseases such as type 2 diabetes.
Animal Biosciences | Boston
We are researching new compounds for veterinary use, and aim to develop proven treatments to prolong youth and expand the lifespan of our four-legged friends, because we believe animals deserve to be beneficiaries of our sophisticated research and we will gain insights applicable to the work of our Daughter companies.
Spotlight Biosciences | Boston | Website
Using proprietary technologies, Spotlight has developed a platform that enables the identification and quantification of thousands of novel peptides, some of which have unique biology relevant to treating human diseases and aging. Drs. David Sinclair and Bogdan Budnik co-founded the company.
Aging Component: Altered Communication & Inflammation
We have identified thousands of novel genes in the human genome, each one could be a new hormone or medicine to treat aging and age-related diseases.
LifeLab | Cambridge, MA
LifeLab is our 24,000-square-foot state-of-the-art lab in Cambridge, Mass. (USA) which serves as the company’s centrally operated laboratory and is able to conduct independent and collaborative research. LifeLab is staffed with a core team to design, execute and analyze studies and it also hosts the Daughter company scientists. LifeLab will benefit from the emerging (AI) platform being developed by LifeAI to optimize the research of each Daughter company and enable Life Biosciences to derive critical data and insight across its hub-and-spoke model.
LifeAI | Boston, MA and New York, NY
LifeAI develops and operates Life Bioscience’s suite of technology to optimize scientific research and development. This secure digital infrastructure will disrupt traditional development and treatment pathways. LifeAI platforms will allow us to identify novel drug targets, biomarkers, and make informed and earlier go, no-go decisions. Specifically, it will:
- Capture, collate, analyze, and present pertinent data to research scientists
- Identify patterns in preclinical and clinical data
- Deliver data and results to consumers and caregivers
Life AI includes the current Lua product, with several other products and platforms in development.
Lua | New York, NY
Supporting the full Life Biosciences family of companies is Lua. Lua currently offers HIPAA-compliant, web- and mobile-access technology that aims to improve medical service delivery and patient outcomes by facilitating communication between consumers and caregivers. The Lua product connects patients and providers directly, allowing them to interact via secure, direct messaging and teleconferencing. Lua will serve as the foundation for LifeAI’s data platforms, utilizing machine learning, neural networks, and other AI tools to speed up novel insights into target medicines.